Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The companyâs lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase inhibitor treatment-naĂŻve and pre-treated patients, and is planned to enter a registrational Phase 2 study in the second half of 2019. Turning Pointâs kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. Source
No articles found.
Commitment to quality, community and people are basic tenets for Quorum Health. As...
Commitment to quality, community and people are...
Addus HomeCare is a comprehensive provider of home and community based services, w...
Addus HomeCare is a comprehensive provider of h...
Amedisys, Inc. is a leading healthcare at home Company delivering personalized hom...
Amedisys, Inc. is a leading healthcare at home ...
NeurMedix, Inc., is a clinical-stage biotechnology company that engages in develop...
NeurMedix, Inc., is a clinical-stage biotechnol...
Bayer is a global enterprise with core competencies in the life science fields of ...
Bayer is a global enterprise with core competen...
Phibro Animal Health Corporation is a leading global diversified animal health and...
Phibro Animal Health Corporation is a leading g...
We are a pharmaceutical company dedicated to the development of best-in-class ther...
We are a pharmaceutical company dedicated to th...
Join the National Investor Network and get the latest information with your interests in mind.